Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Dec 27;13(1):118.
doi: 10.1186/1465-9921-13-118.

Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

Helmut Albrecht  1 , Margaret Vernon, Gail Solomon
Affiliations
Clinical Trial

Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

Helmut Albrecht et al. Respir Res. .

Abstract

Background: Guaifenesin is a component of medicines used to improve symptoms associated with upper respiratory tract infections. Patient-reported outcome instruments are valuable for evaluating symptom improvements; however, a validated tool to assess efficacy of mucoactive drugs does not exist. We compared the efficacy of extended-release guaifenesin with placebo for treatment of symptoms of upper respiratory tract infection using subjective efficacy assessments in a pilot study and confirmed precision of assessments in a validation study.

Methods: The pilot study was a randomized, double-blind study where patients were dosed with either 1200 mg extended-release guaifenesin (n = 188) or placebo (n = 190), every 12 hours for 7 days. Efficacy was assessed using subjective measures including the Daily Cough and Phlegm Diary, the Spontaneous Symptom Severity Assessment and the Wisconsin Upper Respiratory Symptom Survey. End-of-study assessments were completed by patients and investigator. The validation study consisted of two phases. In Phase I, subjects completed interviews to gather evidence to support the content validity of the Daily Cough and Phlegm Diary, the Spontaneous Symptom Severity Assessment and Patient's End-of-Treatment Assessment. Phase II examined the psychometric properties of assessments evaluated in Phase I of the validation study using data from the pilot study.

Results: Subjective measures of efficacy at Day 4 showed the most prominent difference between treatment groups, in favor of guaifenesin. The 8-symptom related questions (SUM8) in the Daily Cough and Phlegm Diary, analyzed as a composite score appeared to be the strongest candidate endpoint for further evaluation. Results from the interviews in Phase I supported the content of the assessments which were validated during Phase II. Treatments were well tolerated.

Conclusions: Results from the clinical pilot and validation studies showed that the SUM8 diary scores were robust and reliable for use as efficacy endpoints in studies of mucoactive drugs.

Trial registration: The study was registered with clinicaltrials.gov (NCT01046136).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition (all-patient population).
Figure 2
Figure 2
Patient’s End-of-Treatment Assessment (mITT population) for the question “Was the study medication effective?”.
See this image and copyright information in PMC

References

    1. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev. 2010;19:127–133. doi: 10.1183/09059180.00003510. - DOI - PMC - PubMed
    1. Dicpinigaitis P, Gayle Y. Effect of guaifenesin on cough reflex sensitivity. Chest. 2003;124:2178–2181. doi: 10.1378/chest.124.6.2178. - DOI - PubMed
    1. Parvez L, Vaidya M, Sakhardande A, Subburaj S, Rajagopalan TG. Evaluation of antitussive agents in man. Pulm Pharmacol. 1996;9:299–308. doi: 10.1006/pulp.1996.0039. - DOI - PubMed
    1. Yuta A, Baranuik JN. Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep. 2005;5:243–251. doi: 10.1007/s11882-005-0044-6. - DOI - PubMed
    1. Rubin BK. An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant and albuterol. Chest. 1999;116:195–200. doi: 10.1378/chest.116.1.195. - DOI - PubMed

Publication types

MeSH terms

Associated data